Glyburide Renal Dose Adjustment by eGFR
Antidiabetics · renal dosing
Glyburide renal dosing by eGFR: the dose-adjustment rule, the key caution, and how to estimate kidney function before prescribing.
Medically reviewed by Dr. Rishi Kumar Kafle, MBBS, MD, FASN. Last reviewed October 2026.
Glyburide is dosed by eGFR: avoid in stage 3-5 CKD.
Reviewed and approved by Dr. Rishi Kumar Kafle, MBBS, MD, FASN. Always confirm against the label.
Renal dosing at a glance
| Parameter | Value |
|---|---|
| Renal estimate used | eGFR |
| Dose adjustment | Avoid in stage 3-5 CKD |
| Key caution | prolonged hypoglycemia |
| Drug class | Antidiabetics |
How Glyburide Is Dosed by eGFR
Glyburide is cleared, wholly or partly, by the kidneys. As filtration falls, the drug or its active metabolites clear more slowly and can accumulate, which raises the risk of prolonged hypoglycemia. The renal dose-adjustment rule for Glyburide is therefore based on eGFR. The summary above is reference-level; the linked FDA label is the authority for the exact numbers.
The Creatinine Clearance Dose-Band Framework
Most renally cleared drugs are adjusted across four broad creatinine clearance bands: above 50, 30-50, 15-30, and below 15 mL/min. Lowering the dose or lengthening the interval as clearance falls is the usual response. Glyburide's own cutoff (above) takes precedence over this general framework when the two differ, because each label sets its renal guidance from that drug's pharmacokinetics and therapeutic window.
| Creatinine clearance (mL/min) | Typical adjustment |
|---|---|
| > 50 | usually standard dosing |
| 30-50 | reduce dose or extend interval for many agents |
| 15-30 | further reduction; some drugs avoided |
| < 15 (or dialysis) | lowest dosing or an alternative agent; dialysis timing may matter |
Why Glyburide Accumulates as Kidney Function Falls
The kidneys normally remove Glyburide (or its active metabolites) at a rate that tracks glomerular filtration. As filtration falls, that removal slows, the drug's effective half-life lengthens, and each dose stays in the body longer before the next is given. Without adjustment, successive doses stack up and the steady-state concentration climbs into the range linked to prolonged hypoglycemia. Lowering the dose or lengthening the interval brings the average concentration back to a safe level and keeps the therapeutic effect. The cutoff is expressed in eGFR rather than serum creatinine alone, because the same creatinine maps to very different clearances depending on age, sex, and body size.
Severe Impairment and Dialysis
At a eGFR below 15 mL/min/1.73m², or on dialysis, dosing for Glyburide usually moves to the lowest end of the range or to an alternative agent, and the timing of doses around a dialysis session can matter when the drug is dialysable. Decisions at this level of kidney function are best made with pharmacy or nephrology input and the patient's measured response, not an estimate alone. See when dialysis is started for context.
How to Calculate eGFR for Glyburide
Estimate the patient's renal function first, then apply the threshold above. Use the eGFR calculator (CKD-EPI 2021) for Glyburide. To see the Cockcroft-Gault figure from the same creatinine, the creatinine clearance calculator gives CrCl in mL/min. For example, a 70-year-old, 70 kg patient with a serum creatinine of 1.4 mg/dL has a Cockcroft-Gault creatinine clearance near 50 mL/min, close to the band where many drugs in this class need adjustment.
Monitoring and Re-Estimating
The key caution for Glyburide is prolonged hypoglycemia. Acute illness, dehydration, contrast, and other nephrotoxic drugs can lower kidney function within days, so re-estimate eGFR whenever the clinical picture changes rather than relying on an old value. A creatinine that is still rising or falling has not reached steady state, and any estimate from it, including for Glyburide, is provisional until the value stabilises.
Re-check renal function and reconsider the Glyburide dose when any of the following appear, since each can signal falling clearance or early accumulation:
- a rising serum creatinine or a falling urine output;
- a new or worsened symptom consistent with prolonged hypoglycemia;
- a new nephrotoxic drug, contrast exposure, dehydration, or acute illness;
- a measured drug level outside its target range, where monitoring applies.
Special Populations
- Older adults: low muscle mass keeps serum creatinine deceptively normal, so clearance, and the safe Glyburide dose, can be lower than the lab value suggests.
- Obesity: total body weight overestimates clearance, so above 130% of ideal body weight the Cockcroft-Gault equation uses adjusted body weight instead.
- Acute kidney injury: a non-steady-state creatinine makes any estimate unreliable; dose conservatively and recheck.
Related Renal Dosing Rules
Neighbouring drugs in the antidiabetics class, with the rule each label sets:
- Dapagliflozin renal dosing (by eGFR): Glycemic efficacy <45 limited; CKD use >=25
- Empagliflozin renal dosing (by eGFR): Glycemic efficacy limited <30; per indication
- Glipizide renal dosing (no CrCl band): Preferred sulfonylurea in CKD; caution
- Metformin renal dosing (by eGFR): <30 contraindicated; 30-45 do not initiate / halve
- Saxagliptin renal dosing (by eGFR): <=45 -> 2.5 mg
- Sitagliptin renal dosing (by eGFR): <45 -> 50 mg; <30 -> 25 mg
Compare all 9 agents side by side in the antidiabetics renal dosing chart, or see related classes: cardiovascular (includes spironolactone, also labelled by eGFR).
Also labelled by eGFR, in other classes: Hydrochlorothiazide, Spironolactone.